SCHEMBL5534

SCHEMBL5534

Clc1ccccc1NC1=NCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 1.00
ADRA2B P18089 1/20 1.00
ADRA2C P18825 1/20 1.00
KMT2A Q03164 3/20 0.51
NISCH Q9Y2I1 1/20 0.51
POLB P06746 3/20 0.51
ALOX15 P16050 2/20 0.47
CYP1A2 P05177 1/20 0.45
TSHR P16473 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TAAR1 Q96RJ0 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5784 0.83 ADRA2A (0.71) ADRA2AADRA2BADRA2CKMT2ANISCH
SCHEMBL5477 0.83 ADRA2A (0.71) ADRA2AADRA2BADRA2CKMT2ANISCH
Hydrochloric Acid SCHEMBL11244477 0.83 ADRA2B (0.71) ADRA2AADRA2BADRA2CKMT2ANISCH
SCHEMBL1669804 0.80 ADRA2A (0.67) ADRA2AADRA2BADRA2CKMT2ANISCH
SCHEMBL5586 0.80 ADRA2A (0.67) ADRA2AADRA2BADRA2CKMT2ANISCH
SCHEMBL6526 0.80 ADRA2A (0.66) ADRA2AADRA2BADRA2CKMT2ANISCH
SCHEMBL6021 0.79 ADRA2A (0.65) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL6475 0.77 ADRA2A (0.62) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL1669736 0.76 ADRA2A (0.61) ADRA2AADRA2BADRA2CKMT2APOLB
Hydrochloric Acid SCHEMBL10369396 0.76 ADRA2A (0.60) ADRA2AADRA2BADRA2CKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238615-A1 Alpha adrenergic receptor modulators ALLERGAN, INC. (US) 2012-09-20 US claimed
CN-102666484-A Adrenergic receptor modulators ALLERGAN INC 2012-09-12 CN claimed
EP-2491017-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS Allergan, Inc. (US) 2012-08-29 EP claimed
WO-2011050030-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN, INC. (US) 2011-04-28 WO claimed
EP-2491017-B1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN INC (US) 2014-08-27 EP disclosed
US-20120238615-A1 Alpha adrenergic receptor modulators ALLERGAN, INC. (US) 2012-09-20 US disclosed
CN-102666484-A Adrenergic receptor modulators ALLERGAN INC 2012-09-12 CN disclosed
EP-2491017-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS Allergan, Inc. (US) 2012-08-29 EP disclosed
WO-2011050030-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN, INC. (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238615-A1 Alpha adrenergic receptor modulators ADRA2C, ADRB2, ADRB1 ADRA2A 4/4885ADRA2B 6/4885ADRA2C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.